Valuation: Guided Therapeutics Inc

Market Cap 24.13M 20.68M 19.35M 17.69M 33.38M 2.31B 33.74M 229M 89.03M 1.16B 90.62M 88.66M 3.84B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 27.01M 23.15M 21.65M 19.8M 37.36M 2.59B 37.76M 256M 99.64M 1.3B 101M 99.22M 4.3B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 05/03/2023
Chief Tech/Sci/R&D Officer 70 01/12/2010
Director TitleAgeSince
Director/Board Member 70 30/11/2016
Director/Board Member 76 09/04/2006
Chairman 67 30/09/2013
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%+6.40%+27.71%+15.73% 232B
+0.06%+8.06%+3.82%-15.60% 151B
-0.35%-5.13%-20.78%+24.72% 132B
+0.92%-2.04%-52.96%-2.60% 71.03B
-1.35%+0.56%-16.53%-12.66% 52.46B
-0.45%-0.84%+11.57%+18.44% 52.16B
+0.33%+4.02%+29.59%+29.02% 43.33B
+0.31%+2.59%+37.70%+50.59% 40.36B
-0.57%+1.56%-1.11%+7.54% 33.51B
Average -0.19%+1.82%+2.11%+12.80% 89.84B
Weighted average by Cap. -0.22%+2.78%+3.73%+10.17%

Financials

2024 2025
Net sales 7K 6K 5.61K 5.13K 9.68K 670K 9.79K 66.41K 25.82K 337K 26.28K 25.71K 1.11M 767K 657K 615K 562K 1.06M 73.44M 1.07M 7.28M 2.83M 36.88M 2.88M 2.82M 122M
Net income -2.42M -2.07M -1.94M -1.77M -3.34M -231M -3.38M -22.93M -8.92M -116M -9.08M -8.88M -385M -3.2M -2.74M -2.56M -2.34M -4.42M -306M -4.47M -30.32M -11.79M -154M -12M -11.74M -508M
Net Debt 1.77M 1.52M 1.42M 1.3M 2.45M 170M 2.48M 16.8M 6.53M 85.15M 6.65M 6.51M 282M 2.88M 2.46M 2.31M 2.11M 3.98M 275M 4.02M 27.28M 10.61M 138M 10.8M 10.56M 458M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-